Dianthus Therapeutics Inc.
DNTH | NASDAQ
$98.42
+$1.95 (+2.02%)
Sep 22, 2026, 11:54 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 1.98M |
Gross Profit | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | -1.98M |
Operating Income | -177.93M | -101.86M | -48.17M | -29.71M | -13.09M | -78.7M |
Interest Income | 16.12M | 17.37M | 4.76M | 1.15M | 100K | 3.77M |
Pretax Income | -162.34M | -84.97M | -43.56M | -28.48M | -13.11M | -74.94M |
Net Income | -162.34M | -84.97M | -43.56M | -28.48M | -13.11M | -74.94M |
Selling & General & Admin | 34.33M | 24.99M | 18.16M | 6.74M | 1.96M | 28.09M |
Research & Development | 145.64M | 83.11M | 32.84M | 29.38M | 12.61M | 48.64M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 179.97M | 108.1M | 51M | 36.12M | 14.56M | 76.72M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 3.77M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 179.97M | 108.1M | 51M | 36.12M | 14.56M | 78.7M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M | 2.75M |
Shares Outstanding (Diluted) | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M | 2.75M |
EPS (Basic) | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 |
EPS (Diluted) | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 |
EBITDA | -161.91M | -84.56M | -43.2M | -28.33M | -11.09M | -72.96M |
EBIT | -162.34M | -84.97M | -43.56M | -28.48M | -13.11M | -74.94M |
Depreciation & Amortization | 428K | 412K | 355K | 147K | 2.02M | 1.98M |
Add to Watchlist
Select watchlists to add or remove DNTH